Foram utilizados 182 camundongos machos, isogênicos, da linhagem C57BL/6 inoculados na orelha direita com 3,0 x 10(6) formas promastigotas da cepa MHOM/BR/PH8 de Leishmania (Leishmania) amazonensis. Os animais foram separados em três grupos: 1) 52 animais tratados com mefloquina (16mg/kg/dia/10 dias), 2) 52 animais tratados com aminosidina [Paramomicina ®] (20mg/kg/dia/20 dias), 3) 78 animais controles, não manipulados. Vinte e seis animais de cada grupo tratado foram sacrificados nove e quinze semanas após a inoculação. Animais do grupo controle foram sacrificados na sexta, nona e décima quinta semanas após a inoculação. Ao final do tratamento, em relação à curva de peso da orelhas, somente nos animais tratados com aminosidina, houve nítida redução do peso em comparação com grupo controle. Na histopatologia verificou-se: a) não houve diferença entre o grupo tratado com mefloquina e o grupo controle; o grupo tratado com aminosidina, ao final do tratamento, teve menor infiltração por macrófagos vacuolizados; b) as avaliações da extensão das áreas de necrose e do nível da fibrose tecidual não mostraram diferenças entre os grupos tratados. Os animais do grupo controle apresentaram fibrose mais acentuada, seis semanas após o fim do tratamento. Pode-se concluir que ocorreu efeito terapêutico reduzido com a mefloquina e houve significativa melhora com a aminosidina. Entretanto, em todos os grupos as lesões não chegaram a curar.

One hundred and eighty-two male inbred C57/BL/6 mice were infected with 3 x 106 Leishmania (Leishmania) amazonensis promastigotes of the MHOM/BR/PH8 strain by means of a subcutaneous injection in the right ear. The animals were separated in three groups: 1) oral mefloquine hydrochloride treatment (16mg/kg/day/10 days), 2) intramuscular aminosidine (Paromomycin®) treatment (20mg/kg/20 days) and 3) control. Twenty six mice of each treated group were sacrificed, one at the end of treatment (nine weeks after inoculation), and one six weeks later (fifteen weeks after inoculation). Control Group animals were sacrificed at weeks six, nine and fifteen after inoculation. There was no significant difference between Group 1 (mefloquine) and Group 3 (control) subjects. Group 2 animals (aminosidine) presented the smallest differences of all, both at the end of the treatment and six weeks later. The histopato-logical parameters have shown the following findings: a) there was no significant difference between the mefloquine treated group and the control group; the group treated with aminosidine showed fewer of vacuolated macrophages than the control group, at week 9 (end of treatment). b) both at the end of treatment and six weeks later, evaluation of tissue necrosis and tissue fibrosis revealed no differences between the treated groups. It was found that six weeks after the end of treatment, mice in the control group presented significantly more severe degrees of fibrosis than mice in the other groups. It can be concluded that mefloquine showed limited therapeutic effect in this experimental model, whereas aminosidine had a significant effect. Nevertheless, neither of them resulted in cure of the lesions.